Journal
CHEST
Volume 142, Issue 6, Pages 1391-1398Publisher
ELSEVIER SCIENCE BV
DOI: 10.1378/chest.12-0150
Keywords
-
Categories
Funding
- National Institutes of Health
- Vanderbilt Clinical and Translational Science Awards grant [UL1 RR024975, 5 T32 HL087738-05, 5 K08 HL093363]
- Vanderbilt 'Diabetes Research and Training Center grant [DK069465]
- Pfizer, Inc
Ask authors/readers for more resources
Background: The 6-min walk test, commonly used to assess exercise capacity and response to therapy in pulmonary arterial hypertension (PAH), has many well-described limitations. Sedentary time is associated with adverse cardiovascular outcomes and reduced quality of life, and measuring sedentary time and physical activity using accelerometry is another potential way to quantify exercise capacity in PAIL. Whether sedentary time is different in patients with PAH vs control subjects is unknown. Methods: Physical activity was measured in 20 patients with PAIL and 30 matched healthy control subjects using accelerometry for 7 consecutive days. Patients with PAH completed standard 6-min walk testing, and baseline demographics were recorded for all study participants. Total daily activity counts, sedentary time, and proportion of time at various activity levels were compared between groups. Results: Sedentary time was significantly higher in patients with PAH (mean, 92.1% daily activity; 95% CI, 89.5-94.8%) than in control subjects (mean, 79.9% daily activity; 95% CI, 76.4%-83.5%; P < .001), and all levels of physical activity were reduced in the PAH group compared with the control group (P < .01 for all). Daily moderate to vigorous physical activity was reduced in the PAH group (7.5 min; 95% CI; 0.8-15.6 min) compared with the control group (mean, 64.7 min; 95% CI, 51.1-78.2 min; P < .001). Activity counts correlated with 6-min walk distance in the PAH group (Spearman rank correlation = 0.72, P < .001). Conclusions: Sedentary time is increased in patients with PAH and may lead to increased risk for metabolic and cardiovascular morbidity. Quantitation of daily activity and sedentary time using accelerometry may be a novel end point for PAIL management and clinical trials. CHEST 2012; 142(6):1391-1398
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available